Navigation Links
Roche and InterMune Reach Definitive Merger Agreement
Date:8/24/2014

pulmonary fibrosis (IPF) is a progressive, irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis (scarring) in the lungs, which hinders the ability of lungs to absorb oxygen.  IPF inevitably causes shortness of breath, and a deterioration in lung function and exercise tolerance.  IPF patients follow different and unpredictable clinical courses and it is not possible to predict if a patient will progress slowly or rapidly, or when the rate of decline may change.  Periods of transient clinical stability in IPF, when they occur, inevitably give way to continued disease progression.  The median survival time from diagnosis is two to three years which makes IPF more rapidly lethal than many malignancies, including breast, ovarian and colorectal cancers.  IPF typically occurs in patients over the age of 45, and tends to affect slightly more men than women.

About Pirfenidone
Pirfenidone is an orally active, anti-fibrotic agent that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key role in fibrosis.  Pirfenidone also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.

On February 28, 2011, the European Commission granted marketing authorization for Esbriet® (pirfenidone) for the treatment of adults with mild to moderate IPF. The approval authorized marketing of Esbriet in all 28 EU member states.  Esbriet has since been approved for marketing in Norway and Iceland. In 2011, InterMune launched commercial sales of pirfenidone in Germany under the trade name Esbriet, and Esbriet is now also commercially available in various European countries, including key markets such as France, Italy an
'/>"/>

SOURCE InterMune
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thermocouples and High End Optical Pyrometer Market by product Types, Applications (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace & Defense) and Geography (North America, Europe, APAC, RoW) - Analysis & Forecast to 2010 - 2020
2. Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche
3. Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo
4. Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare
5. Roche anuncia el lanzamiento del Sistema FLOW para pruebas desarrolladas en laboratorio
6. Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roches latest targeted medicines, Perjeta and Kadcyla
7. Liquidity Services Delivers Surplus Asset Solutions in Support of Hoffmann-La Roches Consolidation Initiative
8. Use of Roches Herceptin Among HER2+ Gastric Cancer Patients May Double in China Over the Next Three Years
9. Roche receives FDA clearance to use additional specimen types for chlamydia and gonorrhea test
10. Landmark study of more than 27,000 women shows favorable results of Roches CINtec PLUS cytology test
11. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 The global ... 49.12 billion by 2020, growing at a CAGR of ... report by Grand View Research, Inc. Monitoring services is ... from 2014 to 2020.      (Logo: ... with rising incidences of chronic diseases such as cancer, ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... 27, 2015 Biosimilars are not generics ... U.S. Food and Drug Administration (FDA) for recognizing ... its draft guidance issued today. The FDA,s draft ... distinguishable names, calling for biological products to bear ... This proposal reflects the agency,s thinking that "there ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... -- At this very moment, FIRMOO is being heatedly discussed ... eyeglasses from FIRMOO are being delivered to various countries of ... so many eyeglasses wearers? In this brand new year of ... platforms, is giving away thousands of free eyeglasses every day ...
... 6, 2012 ViroPharma Incorporated (NASDAQ: ... HALO ) today announced the presentation of positive ... Cinryze® (C1 esterase inhibitor [human]) in combination with ... using Halozyme,s recombinant human hyaluronidase enzyme (rHuPH20), in ...
Cached Medicine Technology:Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 2Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 2ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 4ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 5ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 6ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 7ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 8
(Date:8/29/2015)... ... August 29, 2015 , ... It can ... protection against dribbled urine and sweat. "In order to prevent these problems, I ... EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. ...
(Date:8/29/2015)... New York, NY (PRWEB) , ... August 29, 2015 , ... ... the unofficial end of summer (which astronomically, officially ends on September 22nd this year). ... no summer-induced cyber security hangovers linger on which could prove far more costly than ...
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... An online ... decision to make the purchase of CPAP equipment more affordable by offering shipping at ... all types of CPAP products and orders of any size. My Cpap Store is ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
Breaking Medicine News(10 mins):Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... respiratory problems, CDC report says , , WEDNESDAY, Oct. 22 (HealthDay ... has soared 18 percent in the last decade, with an ... the condition, a new federal report says. , In 2007, ... reported to have had a food or digestive allergy in ...
... $1.60 per share in the third quarter of 2008 -- Medical membership grew by 63,000 ... exceeded 35.3 million at September 30, 2008 -- Benefit expense ratio declined by ... ... increased ...
... 22 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... medical devices worldwide today announced that it will,report ... September 30,2008, after the U.S. market closes on ... conference call at 8:00 a.m. on November,11, 2008 ...
... cost-pressured, limited pipeline biotech and pharmaceutical companies, the market for ... 2012. , ... San Jose, Calif. ... challenges in the form of increasing competition in generic markets, ...
... mother and gluten-free cook/author Theresa Santandrea-Cull - is a collection of ... and wheat products. , ... (PRWEB) October 22, 2008 ... latest recipe book "No Wheat? No Way!" she included ...
... health, how to diagnose disease early and other tips to prolong dogs, lives ... ... cause of death in dogs, affecting more than 10 percent of all dogs ... to this issue - www.yourdogsheart.com - is designed to educate pet ...
Cached Medicine News:Health News:Food Allergies Up 18% Among U.S. Children 2Health News:WellPoint Reports Third Quarter 2008 Results 2Health News:WellPoint Reports Third Quarter 2008 Results 3Health News:WellPoint Reports Third Quarter 2008 Results 4Health News:WellPoint Reports Third Quarter 2008 Results 5Health News:WellPoint Reports Third Quarter 2008 Results 6Health News:WellPoint Reports Third Quarter 2008 Results 7Health News:WellPoint Reports Third Quarter 2008 Results 8Health News:WellPoint Reports Third Quarter 2008 Results 9Health News:WellPoint Reports Third Quarter 2008 Results 10Health News:WellPoint Reports Third Quarter 2008 Results 11Health News:WellPoint Reports Third Quarter 2008 Results 12Health News:WellPoint Reports Third Quarter 2008 Results 13Health News:WellPoint Reports Third Quarter 2008 Results 14Health News:WellPoint Reports Third Quarter 2008 Results 15Health News:WellPoint Reports Third Quarter 2008 Results 16Health News:WellPoint Reports Third Quarter 2008 Results 17Health News:WellPoint Reports Third Quarter 2008 Results 18Health News:WellPoint Reports Third Quarter 2008 Results 19Health News:WellPoint Reports Third Quarter 2008 Results 20Health News:WellPoint Reports Third Quarter 2008 Results 21Health News:WellPoint Reports Third Quarter 2008 Results 22Health News:WellPoint Reports Third Quarter 2008 Results 23Health News:WellPoint Reports Third Quarter 2008 Results 24Health News:WellPoint Reports Third Quarter 2008 Results 25Health News:Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008 2Health News:Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc. 3Health News:Now Available Online, Beneficial Recipe Book Offers Wheat-Free, Gluten-Free Options for Healthy Living 2Health News:New Web Site Devoted to Canine Heart Disease - A Leading Cause of Death in Dogs 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: